Dr. Rausch’s study was sponsored by her employer, GlaxoSmithKline. The findings are supportive of an earlier study by other investigators, who found that the risk of hospitalization for stroke was up to twofold greater within the first 90 days after diagnosis of HZ in patients with rheumatoid arthritis and other autoimmune diseases than the stroke rate 366-730 days after HZ (Arthritis Rheumatol. 2017.69[2]:439-46).